Comprehensive review examines m5C RNA modification's role in gastrointestinal cancers, suggesting its potential as a biomarker and therapeutic target.
5-methylcytosine (m5C) modification has emerged as a novel epigenetic modification of ribonucleic acids (RNAs), encompassing messenger RNAs (mRNAs) and non- coding RNAs, in recent years. This reversible modification, which is regulated by m5C regulators consisting of methyltransferases, demethyltransferases, and RNA-binding proteins, modulates all aspects of RNA metabolism and gene expression. Gastrointestinal (GI) cancers are prevalent malignancies with a high mortality rate globally. Accumulating evidence has indicated the significant role of m5C RNA modification in the tumorigenesis and progression of GI cancers. In this review, we provide a comprehensive overview of the functions and underlying molecular mechanisms of m5C RNA modification in RNA metabolism for the regulation of tumor biology, including cell proliferation, apoptosis, invasion/metastasis, chemoresistance, and other biological functions. Furthermore, we summarize the specific role of m5C modification in GI cancers and propose some insights regarding its application as a tumor biomarker and therapeutic target, aiming to offer a new perspective for m5C modification in GI cancer diagnosis and treatment in the future.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: